U.S. Markets closed

CLASS ACTION UPDATE for EBIX, CYDY and FGEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 21, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

EBIX Shareholders Click Here: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=15002&wire=1
CYDY Shareholders Click Here: https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15002&wire=1
FGEN Shareholders Click Here: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=15002&wire=1

* ADDITIONAL INFORMATION BELOW *

Ebix, Inc. (NASDAQ:EBIX)

EBIX Lawsuit on behalf of: investors who purchased November 9, 2020 - February 19, 2021
Lead Plaintiff Deadline : April 23, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ebix-inc-loss-submission-form?prid=15002&wire=1

According to the filed complaint, during the class period, Ebix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix's gift card business in India during the fourth quarter of 2020; (2) there was a material weakness in Company's internal controls over the gift or prepaid revenue transaction cycle; and (3) the Company's independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix's outside legal counsel; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

CytoDyn Inc. (OTCQB:CYDY)

CYDY Lawsuit on behalf of: investors who purchased March 27, 2020 - March 9, 2021
Lead Plaintiff Deadline : May 17, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cytodyn-inc-loss-submission-form?prid=15002&wire=1

According to the filed complaint, during the class period, CytoDyn Inc. made materially false and/or misleading statements and/or failed to disclose that: CytoDyn securities were actively traded over the counter (OTC) in the United States. While the exact number of Class members is unknown to Plaintiff at this time and can be ascertained only through appropriate discovery, Plaintiff believes that there are hundreds or thousands of members in the proposed Class. Record owners and other members of the Class may be identified from records maintained by CytoDyn or its transfer agent and/or OTC Markets and may be notified of the pendency of this action by mail, using the form of notice similar to that customarily used in securities class actions.

FibroGen, Inc. (NASDAQ:FGEN)

FGEN Lawsuit on behalf of: investors who purchased November 8, 2019 - April 6, 2021
Lead Plaintiff Deadline : June 11, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=15002&wire=1

According to the filed complaint, during the class period, FibroGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/641673/CLASS-ACTION-UPDATE-for-EBIX-CYDY-and-FGEN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders